The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor
Abstract
Purpose: To investigate the safety and tolerability and to explore the pharmacokinetic and pharmacodynamic profile of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with solid tumors that express epidermal growth factor receptor (EGFR). Patients and Methods: This was a phase I dose-escalation trial of EMD72000 in patients with advanced, EGFR-positive, solid malignancies that were not amenable to any established chemotherapy or radiotherapy treatment. EMD72000 was administered weekly without routine premedication until disease progression or unacceptable toxicity. Results: Twenty-two patients were treated with EMD72000 at five different dose levels (400 to 2,000 mg/wk). National Cancer Institute common toxicity criteria grade 3 headache and fever occurring after the first infusion were dose limiting at 2,000 mg/wk; thus, the maximum-tolerated dose was 1,600 mg/wk. No other severe side effects, especially no allergic reactions or diarrhea, were observed. Acneiform skin reaction was the most common toxicity, but it was mild, with grade 1 in 11 patients (50%) and grade 2 in three patients (14%). Pharmacokinetic analyses demonstrated a predictable pharmacokinetic profile for EMD72000 . Pharmacodynamic studies on serial skin biopsies revealed that EMD72000 effectively abrogated EGFR-mediated cell signaling (eg, reduced phosphorylation of EGFR and mitogen-activated protein kinase), with no alteration in total EGFR protein. Objective responses (23%; 95% CI, 8% to 45%) and disease stabilization (27%; 95% CI, 11% to 50%) were achieved at all dose levels, and responding patients received treatment for up to 18 months without cumulative toxicity. Conclusion: Treatment with EMD72000 was well tolerated and showed evidence of activity in heavily pretreated patients with EGFR-expressing tumors. EMD72000 at the investigated doses significantly inhibited downstream EGFR-dependent processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Self-citationLigand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor
Schlessinger, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00966-2 · Cited by 993
Single-molecule imaging of EGFR signalling on the surface of living cells
Sako, Y., Minoghchi, S., & Yanagida, T. (2000) · Nature Cell Biology · doi:10.1038/35004044 · Cited by 890
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Self-citationBaselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Self-citationFerrara, N. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37264 · Cited by 546
Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R. S., LoRusso, P. M., Rischin, D., Sauleda, S., Gee, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.110 · Cited by 528
Self-citationDevelopment of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy
Raymond, E., Faivre, S., & Armand, J. P. (2000) · Drugs · doi:10.2165/00003495-200060001-00002 · Cited by 398
ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases
Olayioye, M. A., Beuvink, I., Horsch, K., Daly, J. M., & Hynes, N. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17209 · Cited by 367
The EGF receptor - an essential regulator of multiple epidermal functions.
Jost, M., Kari, C., & Rodeck, U. (2000) · PubMed · Cited by 302
ARTEAGA, C. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70085-7 · Cited by 302
Albanell, J., Codony‐Servat, J., Rojo, F., Campo, J. M. D., Sauleda, S., Anido, J., Raspall, G., Giralt, J., Roselló, J., Nicholson, R. I., et al. (2001) · PubMed · Cited by 273
Self-citationKettleborough, C. A., Saldanha, J., Heath, V. J., Morrison, C. J., & Bendig, M. M. (1991) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/4.7.773 · Cited by 197
The Role of the Epidermal Growth Factor Receptor Family in Mammary Tumorigenesis and Metastasis
Kim, H., & Muller, W. J. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4706 · Cited by 190
Epidermal Growth Factor Receptor Family and Chemosensitization
Mendelsohn, J., & Fan, Z. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.5.341 · Cited by 171
Lynch, D. H., & Yang, X. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31522 · Cited by 128
van den Brink, M., van den Hout, W. B., Stiggelbout, A. M., Kranenbarg, E. M., Marijnen, C. A. M., van de Velde, C. J. �., & Kievit, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.198 · Cited by 100
Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839
Albanell, J., Rojo, F., & Baselga, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90283-0 · Cited by 88
Self-citationSafety experience with IMC-C225, an anti-epidermal growth factor receptor antibody
Needle, M. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70091-2 · Cited by 84
Epidermal growth factor receptor-targeted therapy in colorectal cancer
O'Dwyer, P. J., & BENSONIII, A. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70086-9 · Cited by 83
Baselga, J. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.9.2217 · Cited by 76
Self-citationSafety experience with IMC-C225, an anti-epidermal growth factor receptor antibody
Needle, M. N. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.35648 · Cited by 70
Pemetrexed: Single-agent and combination phase I study overview
Boyer, M. J., Rivory, L. P., & Clarke, S. J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37464 · Cited by 16
Patel, J., Miller, V. A., Kris, M. G., Shah, N., Tyson, L. B., Pizzo, B., Zakowski, M. F., Cespon, M., Heelan, R. T., & Johnson, D. (2003) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(03)90089-9 · Cited by 14
Franke, H. R., & Vermes, I. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00293-9 · Cited by 13
Cited by
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Self-citationEpidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Self-citation
Metadata
- Authors
- Vanhoefer, U., Tewes, M., Rojo, F., Dirsch, O., Schleucher, N., Rosen, O., Tillner, J., Kovar, A., Braun, A. H., Trarbach, T., Seeber, S., Harstrick, A., & Baselga, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-01-01
- Volume
- 22
- Issue
- 1
- Pages
- 175-184
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103384680
- Cited by
- 261
- References
- 29
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.